Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Cost of Revenue: 2009-2024

Historic Cost of Revenue for Gyre Therapeutics (GYRE) over the last 6 years, with Dec 2024 value amounting to $57.5 million.

  • Gyre Therapeutics' Cost of Revenue rose 11.89% to $15.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.2 million, marking a year-over-year increase of 1.93%. This contributed to the annual value of $57.5 million for FY2024, which is 5.96% down from last year.
  • As of FY2024, Gyre Therapeutics' Cost of Revenue stood at $57.5 million, which was down 5.96% from $61.2 million recorded in FY2023.
  • In the past 5 years, Gyre Therapeutics' Cost of Revenue registered a high of $61.2 million during FY2023, and its lowest value of $6.1 million during FY2020.
  • Its 3-year average for Cost of Revenue is $57.6 million, with a median of $57.5 million in 2024.
  • As far as peak fluctuations go, Gyre Therapeutics' Cost of Revenue spiked by 634.93% in 2022, and later decreased by 5.96% in 2024.
  • Over the past 5 years, Gyre Therapeutics' Cost of Revenue (Yearly) stood at $6.1 million in 2020, then climbed by 21.76% to $7.4 million in 2021, then spiked by 634.93% to $54.2 million in 2022, then climbed by 12.76% to $61.2 million in 2023, then declined by 5.96% to $57.5 million in 2024.